Big Pharma pursues epigenetics for cancer breakthroughs

Big Pharma companies like GlaxoSmithKline, Eli Lilly and Novartis are among the drugmakers pursuing new cancer treatments based on epigenetics--an approach that aims to reprogram abnormal DNA that causes cells to become cancerous. Epigenetics is already used in oncology drugs that treat certain blood-cancer disorders, but the real test will be to see whether it can also be applied to solid tumor cancers. Piece

Suggested Articles

Quench Bio is going after a family of proteins involved in inflammatory cell death to treat inflammatory diseases in a more holistic way.

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.